ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Late-Breaking 2019"

  • Abstract Number: L13 • 2019 ACR/ARP Annual Meeting

    Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Philip J. Mease1, Proton Rahman 2, Alice B. Gottlieb 3, Elizabeth Hsia 4, Alexa Kollmeier 5, Xie Xu 6, Ramanand Subramanian 5, Prasheen Agarwal 5, Shihong Sheng 5, Bei Zhou 5, Désirée van der Heijde 7 and Iain McInnes 8, 1Swedish Medical Center and University of Washington, Seattle, Washington, 2Memorial University of Newfoundland, Newfoundland, Canada, 3Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, 5Janssen Research & Development, LLC, Spring House, Pennsylvania, 6Janssen Research & Development, LLC, Spring House, 7Leiden University Medical Center, Leiden, Netherlands, 8Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
  • Abstract Number: L14 • 2019 ACR/ARP Annual Meeting

    Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance

    Peter Nash1, Laura Coates 2, Philip J. Mease 3, Alan Kivitz 4, Dafna Gladman 5, Frank Behrens 6, James C Wei 7, Dona Fleishaker 8, Joseph Wu 8, Cunshan Wang 8, Ana Romero 9, Lara Fallon 10, Ming-Ann Hsu 8 and Keith Kanik 8, 1Griffith University, Brisbane, Queensland, Australia, 2University of Oxford, Oxford, United Kingdom, 3Swedish Medical Center and University of Washington, Seattle, Washington, 4Altoona Center for Clinical Research, Duncansville, 5University of Toronto, Toronto, Canada, 6CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, 7Chung Shan Medical University, Taichung City, Taiwan (Republic of China), 8Pfizer Inc, Groton, Connecticut, 9Pfizer Inc, Barcelona, Spain, 10Pfizer Inc, Montreal, Canada

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Tofacitinib monotherapy has not been previously studied in PsA. This sub-study of…
  • Abstract Number: L15 • 2019 ACR/ARP Annual Meeting

    Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial

    David Isenberg1, Richard Furie 2, Nicholas Jones 3, Pascal Guibord 4, Joshua Galanter 5, Chin Lee 3, Anna McGregor 3, Balazs Toth 3, Julie Rae 3, Olivia Hwang 3, Pedro Miranda 6, Viviane de Souza 7, Juan Jaller-Raad 8, Anna Maura Fernandes 9, Rodrigo Garcia Salinas 10, Leslie Chinn 3, Michael Townsend 11, Alyssa Morimoto 3 and Katie Tuckwell 12, 1University College London, London, United Kingdom, 2Northwell Health, Great Neck, NY, 3Genentech, Inc., South San Francisco, California, 4Hoffmann-La Roche Limited, Mississauga, Canada, 5Genentech, Inc., SOUTH SAN FRANCISCO, 6Centro Estudios Reumatologicos, Santiago, Chile, 7Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil, 8Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia, 9Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil, 10Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, 11Genentech, Inc., San Fransisco, 12Genentech, Inc., South San Francisco, CA

    Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…
  • Abstract Number: L16 • 2019 ACR/ARP Annual Meeting

    GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study

    Samuel Deshayes1, Venceslas Bourdin 2, Christian Creveuil 3, Jonathan Boutemy 1, Eric Liozon 4, Xavier Kyndt 5, Laurent Sailler 6, Grégory Pugnet 6, Hubert de Boysson 1, Eric Hachulla 7, Marc André 8, Julie Magnant 9, Jacques Boddaert 10, Olivier Fain 11, Arsène Mékinian 11, Mohamed Hamidou 12, Loïc Guillevin 13, Cédric Landron 14, Isabelle Marie 15, Yannick Chène 3, Laurent Becquemont 16, Céline Verstuyft 2 and Boris Bienvenu 17, 1Department of Internal Medicine, Caen University Hospital, Caen, France, 2INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Paris, France, 3Biomedical Reserch Unit, Caen University Hospital, Caen, France, 4Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, 5Department of Internal Medicine and Nephrology, Valenciennes Hospital, Valenciennes, France, 6Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, 7Department of Internal Medicine and Clinical Immunology, Lille University Hospital, Lille, France, 8Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, 9Department of Internal Medicine, Tours University Hospital, Tours, France, 10Department of Geriatrics, Pitié-Salpêtrière-Charles Foix University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, 11Department of Internal Medicine, Saint Antoine University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, 12Department of Internal Medicine, Nantes University Hospital, Nantes, France, 13Department of Internal Medicine, Cochin University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, 14Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, 15Department of Internal Medicine, Rouen University Hospital, Rouen, France, 16INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Le Kremblin Bicêtre, France, 17Department of Internal Medicine, Saint Joseph Hospital, Marseille, France

    Background/Purpose: Giant cell arteritis (GCA) is the most common cause of primary vasculitis in adults. Corticosteroids are the cornerstone of the treatment. However, approximately 50%…
  • Abstract Number: L01 • 2019 ACR/ARP Annual Meeting

    Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

    Yinzhu Jin 1, Hemin Lee 1, Moa Lee 2, Joan Landon 3, Joseph Merola 4, Rishi Desai 5 and Seoyoung C. Kim1, 1Brigham and Women's Hospital and Harvard Medical School, Boston, 2University of North Carolina Chapel Hill, Chapel Hill, North Carolina, 3Brigham and Women's Hospital, Boston, Massachusetts, 4Harvard Medical School, Brigham and Women's Hospital, Boston, 5Brigham and Women's hospital, Boston

    Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
  • Abstract Number: L17 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial

    Eric Morand1, Richard Furie 2, Yoshiya Tanaka 3, Ian Bruce 4, Anca Askanase 5, Christophe Richez 6, Sang-Cheol Bae 7, Philip Brohawn 8, Lilia Pineda 9, Anna Berglind 10 and Raj Tummala 9, 1Monash University, Melbourne, Victoria, Australia, 2Zucker School of Medicine at Hofstra/Northwell, New York, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 5Columbia University, New York, 6CHU de Bordeaux-GH Pellegrin, Bordeaux, France, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8Former employee of AstraZeneca, Gaithersburg, Maryland, 9AstraZeneca, Gaithersburg, Maryland, 10AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
  • Abstract Number: L02 • 2019 ACR/ARP Annual Meeting

    Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity

    Naizhuo Zhao 1, Audrey Smargiassi 2, Marianne Hatzopoulou 3, Ines Colmegna 4, Marie Hudson 5, Marvin Fritzler 6, Philip Awadalla 7 and Sasha Bernatsky8, 1Research Institute of the McGill University Health Centre, Montreal, Canada, 2University of Montreal, Montreal, Canada, 3University of Toronto, Toronto, Canada, 4McGill University Health Center, Montreal, QC, Canada, 5Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, 6Cumming School of Medicine, University of Calgary, Calgary, Canada, 7Ontario Institute for Cancer Research, Toronto, Canada, 8Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
  • Abstract Number: L18 • 2019 ACR/ARP Annual Meeting

    A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study

    Di Wu1, Jing Li 2, Dong Xu 2, Wenxiang Wang 3, Lin Li 4, Jianmin Fang 3 and Fengchun Zhang 5, 1Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), 2Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Beijing, China (People's Republic), 3RemeGen, Ltd., Yantai, China (People's Republic), 4RemeGen, Ltd., Beijing, China (People's Republic), 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)

    Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…
  • Abstract Number: L03 • 2019 ACR/ARP Annual Meeting

    NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia

    Steven Harte 1, Leslie Arnold 2, Eric Ichesco 1, Christopher Crumb 1, Mary Suh 3, Laurel Sindelar 3, Chelsea Kaplan 1, Tony Larkin 1, Andrew Schrepf 1, Daniel Clauw 4, Stephen Sainati 3 and Richard Harris1, 1University of Michigan, Ann Arbor, 2University of Cincinnati College of Medicine, Cincinnati, 3Aptinyx Inc, Evanston, 4Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Fibromyalgia (FM) is a chronic, debilitating disease typified by widespread musculoskeletal pain and accompanied by fatigue, sleep disturbance, memory issues, and mood disorders.  FM…
  • Abstract Number: L19 • 2019 ACR/ARP Annual Meeting

    Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients

    Simon Bowman1, Robert Fox 2, Thomas Dörner 3, Xavier Mariette 4, Athena Papas 5, Thomas Grader-Beck 6, Benjamin A. Fisher 7, Filipe Barcelos 8, Salvatore De Vita 9, Hendrik Schulze-Koops 10, Robert J. Moots 11, Guido Junge 12, Janice Woznicki 13, Monika Sopala 12, Wen-Lin Luo 13 and Wolfgang Hueber 12, 1University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 2Scripps Memorial Hospital and Research Institute, La Jolla, California, 3Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Tufts School of Dental Medicine, Massachusetts, 6Johns Hopkins University, Baltimore, 7University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, 8Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, 9Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, 10Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, 11Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 12Novartis Pharma AG, basel, Switzerland, 13Novartis Pharmaceuticals Corporation, New Jersey

    Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
  • Abstract Number: L04 • 2019 ACR/ARP Annual Meeting

    Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease

    Maaman Bashir1, Katherine Sherman 2, Sara K. Tedeschi 3 and Ann Rosenthal 1, 1Medical College of Wisconsin, Milwaukee, 2Milwaukee VAMC, Milwaukee, 3Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston

    Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from precipitation of calcium pyrophosphate (CPP) crystals in joints. Prior studies demonstrated that vascular calcification is more common…
  • Abstract Number: L20 • 2019 ACR/ARP Annual Meeting

    A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks

    Josef Smolen1, Peter Nash 2, Hasan Tahir 3, Hendrik Schulze-Koops 4, Lingnan Li 5, Maja Hojnik 6, Amanda Gellett 5, Soyi Liu-Leage 7, Sreekumar Pillai 7 and Philip J. Mease 8, 1Medical University of Vienna, Vienna, Austria, 2Griffith University, Brisbane, Queensland, Australia, 3Royal Free London NHS Trust, London, United Kingdom, 4Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, 5Eli Lilly and Company, Indianapolis, Indiana, 6Eli Lilly and Company, Indianapolis, IN, 7Eli Lilly and Company, Indianapolis, 8Swedish Medical Center and University of Washington, Seattle, Washington

    Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
  • Abstract Number: L05 • 2019 ACR/ARP Annual Meeting

    Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA

    Benjamin Hsu1, Jennifer Visich 2, Mark Genovese 3, Kimberly Walter 2, Mahru An 4, Remi-Martin Laberge 4 and Jamie Dananberg 4, 1Unity Biotechnology, Brisbane, 2Unity Biotechnology, Brisbane, California, 3Stanford University, Stanford, CA, 4Unity Biotechnology, Brisbane, CA

    Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…
  • Abstract Number: L21 • 2019 ACR/ARP Annual Meeting

    Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study

    Atul Deodhar1, Ricardo Blanco 2, Eva Dokoupilova 3, Marleen van de Sande 4, Stephen Hall 5, Anna Wiksten 6, Brian Porter 7, Hanno Richards 6, Sibylle Haemmerle 6 and Jürgen Braun 8, 1Oregon Health & Science University, Portland, OR, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, 4Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, 5Monash University, Melbourne, Australia, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

    Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
  • Abstract Number: L06 • 2019 ACR/ARP Annual Meeting

    Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids

    Fabrizio De Benedetti1, Paul Brogan 2, Alexei A. Grom 3, Pierre Quartier 4, Rayfel Schneider 5, Jordi Antón 6, Claudia Bracaglia 7, Manuela Pardeo 8, Giulia Marucci 8, Emanuela Sacco 9, Despina Eleftheriou 10, Charalampia Papadopoulou 11, Philippe Jacqmin 12, maria ballabio 13 and Cristina de Min 13, 1Bambino Gesù Children's Hospital, Rome, Italy, 2Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Necker Hospital, Paris, France, 5Hospital for Sick Children, Toronto, ON, Canada, 6Hospital Sant Joan de Déu, Barcelona, Spain, 7Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 8Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 9Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, 10UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section,, london, United Kingdom, 11UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section, london, United Kingdom, 12MnS, Dinant, Belgium, 13Sobi AG, basel, Switzerland

    Background/Purpose: MAS is a severe complication of rheumatic diseases, most frequently sJIA and adult-onset Still’s disease. It is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias,…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology